We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
XORTX Therapeutics Inc | CSE:XRX | CSE | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.80 | 3.24 | 24.00 | 0 | 00:00:00 |
BW20030611002104 20030612T060019Z UTC ( BW)(XEROX-CORP.)(XRX) Capital Reorganisation Business Editors UK REGULATORY NEWS STAMFORD, Conn.--(BUSINESS WIRE)--June 12, 2003-- Xerox Announces $3.1 Billion Recapitalization Strategy; Commitments Received for $1 Billion Credit Facility Xerox Corporation (NYSE: XRX) announced today a comprehensive recapitalization strategy of about $3.1 billion that will delever and strengthen the company's balance sheet, extend debt maturities and provide operating and financial flexibility. The financing plan includes common stock, mandatory convertible preferred securities, senior unsecured notes and a bank financing transaction. Xerox has already received commitments from Citigroup, Deutsche Bank, Goldman Sachs, JPMorgan, Merrill Lynch and UBS for a new $1 billion credit facility consisting of a $700 million revolving facility and a $300 million term loan, both maturing in September 2008. This new credit facility is contingent upon Xerox raising $1.5 billion through its financing plan, including at least $500 million of common and preferred equity. Xerox plans to use proceeds from the recapitalization transaction and the new term loan as well as a portion of its current cash balance to repay and terminate the $3.1 billion outstanding from its current bank facility. As part of the recapitalization strategy Xerox intends to issue the following: -- Approximately 40 million shares of common stock valued at $434 million based on Monday's closing stock price of $10.84. -- Approximately $650 million of mandatory convertible preferred securities. -- Approximately $1 billion of a combination of 7-year and 10-year senior unsecured notes. Subject to market conditions, Xerox intends to complete the recapitalization transaction by the end of this month. As a result, the company expects that its reduced interest expense will largely offset the dilutive impact of the additional shares in the second half of this year and in 2004. To recognize the remaining unamortized fees associated with the 2002 credit facility, Xerox will record a $70 million pre-tax charge in the second quarter. Excluding this charge, the company continues to expect that second-quarter earnings will be in the range of 9 cents to 12 cents per share. The common stock, mandatory convertible preferred securities and senior unsecured notes will be issued by Xerox and sold under the company's $3 billion universal shelf registration statement. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Xerox including shares of common stock, shares of mandatory convertible preferred stock or senior unsecured notes. Shares of common stock, shares of mandatory convertible preferred stock or senior unsecured notes will not be sold in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful. A copy of the prospectuses in the offerings of the common stock, mandatory convertible preferred securities and senior unsecured notes may be obtained from: JPMorgan, 277 Park Avenue, 8th Floor, New York, NY, 10172. For additional information about The Document Company Xerox, please visit our Worldwide Web site at www.xerox.com/investor. This release contains forward-looking statements and information relating to Xerox that are based on our beliefs as well as assumptions made by and information currently available to us. The words "anticipate," "believe," "estimate," "expect," "intend," "will" and similar expressions, as they relate to us, are intended to identify forward-looking statements. Actual results could differ materially from those projected in such forward-looking statements. Information concerning certain factors that could cause actual results to differ materially is included in the company's Form 10-Q for the quarter ended March 31, 2003, as filed with the SEC. XEROX(R), The Document Company(R) and the digital X(R) are trademarks of XEROX CORPORATION. Short Name: Xerox Corporation Category Code: CAR Sequence Number: 00005742 Time of Receipt (offset from UTC): 20030611T212005+0100 --30--DB/ny CONTACT: Xerox Corporation James A. Ramsey, 203/968-3807 Fax: 203/968-3944 James.Ramsey@usa.xerox.com or Cynthia B. Johnston, 203-968-3489 Fax: 203/968-3944 Cindy.Johnston@usa.xerox.com KEYWORD: CONNECTICUT UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: BANKING COMPUTERS/ELECTRONICS HARDWARE PUBLISHING SOURCE: Xerox Corporation Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
1 Year XORTX Therapeutics Chart |
1 Month XORTX Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions